Methods: Population pharmacokinetic and E-R models were developed based on two Phase I, four Phase II, and four Phase III studies.
Results: Variability in empagliflozin exposure was primarily affected by estimated glomerular filtration rate (eGFR) (less than twofold increase in exposure in patients with severe renal impairment). Consistent with its mode of action, the efficacy of empagliflozin was increased with elevated baseline plasma glucose levels and attenuated with decreasing renal function, but was still maintained to nearly half the maximal effect with eGFR as low as 30 mL/min/1.73 m 2 . All other investigated covariates, including sex, body mass index, race, and age did not alter the PK or efficacy of empagliflozin to a clinically relevant extent. Compared with placebo, empagliflozin administration was associated with an exposure-independent increase in the incidence of genital infections and no significant change in the risk of UTI, hypoglycemia, or volume depletion.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive disease, and currently available oral antidiabetic agents, although initially effective, often fail to maintain long-term glycemic control or are associated with side effects, such as hypoglycemia, weight gain, and edema [1, 2] .
Hence, there remains a need for new or alternative therapies that can be used alone or in combination with other antidiabetic agents, and provide sustained improvements in glycemic control without clinically limiting side effects.
A new approach to the management of T2DM involves the reduction of renal glucose reabsorption through inhibition of the sodium glucose cotransporter 2 (SGLT2), found in the brush border of the proximal convoluted tubule of the renal nephron [3] . The inhibition of SGLT2 lowers the renal threshold for glucose reabsorption and increases urinary glucose excretion (UGE) [4] [5] [6] . Thereby, SGLT2 inhibition lowers postprandial and fasting plasma glucose (FPG) [7] , and reduces glycated hemoglobin (HbA1c) [8] . Empagliflozin is an SGLT2 inhibitor that has been evaluated in Caucasian [9] and Japanese [10] healthy volunteers, and patients with T2DM [7, 11] , and demonstrated dose-proportional drug exposure and an increasing UGE with rising empagliflozin doses, up to 10-25 mg [12] . Phase III studies of empagliflozin, administered as monotherapy or add-on to other antidiabetic therapies, have shown improvements in glycemic control, in addition to modest reductions in body weight and blood pressure.
Placebo-corrected reductions in HbA1c have been demonstrated both with empagliflozin monotherapy (-0.7% for 10 mg and -0.9% for 25 mg) [13] , and as add-on therapy (-0.4% to -0.7% for 10 mg and -0.5% to -0.7% for 25 mg) [14] [15] [16] [17] , in addition to reductions in FPG (monotherapy, -1.7 mM for 10 mg, and -2.0 mM for 25 mg; add-on therapy, -0.9 to -1.5 mM for 10 mg and -1.2 to -1.8 mM for 25 mg) [13] [14] [15] [16] [17] .
The aim of the present analysis was to characterize the population pharmacokinetics (PK) and exposure-response (E-R) for efficacy and safety/tolerability endpoints of empagliflozin in patients with T2DM. This study extends the findings of previous analyses [18, 19] , which described the PK and pharmacodynamics (PD) (UGE, FPG, and HbA1c) based on Phase I and II data only. The focus of the present study was to evaluate the impact of covariates, including age, body mass index (BMI), sex, and estimated glomerular filtration rate (eGFR) on the PK and E-R of empagliflozin. The model was used to simulate HbA1c lowering in patient subpopulations of special interest, including elderly patients and individuals with renal impairment.
METHODS

Population PK Analysis
Model Development
A previously developed two-compartment model with a lagged first-order absorption and first-order elimination [19] (Table S1 in the supplementary material). The absorption lag time was fixed to 0.5 h, and data obtained within the first hour after dosing were excluded from analysis.
The covariates were chosen based on one or a combination of the following: findings from previous analysis (CL/F: age, BMI, race, total protein, eGFR; V 2 /F: sex, race, total protein, BMI; k a : race), scientific interest and relevance to the development programme (V 2 /F: age, race; k a : sex), physiological/mechanistic plausibility (CL/F: eGFR; k a : age). Additionally, some covariates were identified during the graphical covariate analysis (CL/F: sex, smoking status).
Laboratory tests were included in the full covariate analysis only if a plausible mechanism for their influence on PK variability was known.
The full covariate modeling approach that was implemented is a simplification of a previously described global model approach [20] , which emphasizes parameter estimation rather than stepwise hypothesis testing.
Predefined covariate parameter relationships were identified based on exploratory graphics, scientific interest, mechanistic plausibility, or prior knowledge, and a full model was constructed with attention to avoiding correlation or co-linearity in predictors.
Population typical parameters, including fixed effects parameters (covariate coefficients and structural model parameters) and random effects parameters were estimated using
Solutions, Hanover, MD, USA). Patient-level random effects were included for CL/F, k a , and V 3 /F; these parameters were assumed to be log-normal distributed. Residual unexplained error was modeled with a proportional error model. Further detail is given in Table S1 
Model Evaluation
The precision of the PK model parameter estimates was investigated using a non-parametric bootstrap procedure. In addition, Monte Carlo simulations were performed to evaluate the predictive performance of the population PK model for dose-normalized maximum and minimum concentration (C max and C min , respectively).
Exposure-Response Analysis (Efficacy)
Model Development
A population PK/PD analysis was conducted using the non-linear mixed-effects modeling software, NONMEM Ò , to investigate the impact of empagliflozin exposure and selected covariate on FPG and HbA1c. In the population PK/PD model, an increase in empagliflozin exposure was associated with an increase in glucose elimination leading to a reduction in FPG over time (Eq. 1), and thereby, a reduction in HbA1c (Eq. 2). The model structure used in the present study was based on a previously developed PK/PD model [18] and is similar to a model reported for an analysis of multiple treatments for T2DM [21] . 
In turn, changes in FPG over time were modeled to impact HbA1c production, as described by Eq. 2.
where k HbA1c in;i was the first-order production rate constant of HbA1c, HbA1c i,j was the HbA1c value for the ith patient at the jth collection time, k HbA1c out;i was the first-order elimination rate constant, and HbA1c limit was the boundary condition.
Based on this structural model, a covariate analysis was performed. 
Model Evaluation
The model development was performed in a stepwise manner. First, an initial model was developed excluding studies 6 and 10 (as a result of data availability). For this initial model, an external simulation check was performed, where the HbA1c reductions in study 6 were predicted and compared with the original data from this trial. Study 6 was selected for external evaluation as its patient population was similar to the one used for model development. Finally, the model was updated using all studies, including studies 6 and 10. The precision of the final PK/PD model parameter estimates was investigated using a non-parametric bootstrap procedure. In addition, Monte Carlo simulations were performed to evaluate the predictive performance of the final population PK/PD model for change in HbA1c.
Simulations
The simulations performed for the final predictive check provided guidance on the typical magnitude and time-course of HbA1c response. Additional simulations (n = 1000 studies, including inter-individual ? residual variability) were performed to assess HbA1c lowering after 24 weeks of treatment in subpopulations of special interest, i.e., patients with renal impairment (study 10) and patients of advanced age (final PK/PD dataset, patients aged 75-85 years). The covariate values (such as BMI, eGFR, and age) that were associated with the patients in each subpopulation were accounted for in the simulations. For the purpose of the simulations, it was assumed that each patient received either 10 mg (scenario 1) or 25 mg (scenario 2) empagliflozin once daily.
Only patients on active treatment in the original study were considered because the calculation of the individual AUC ss values required an estimate of CL/F i .
Exposure-Response Analysis (Safety)
Model Development
The safety/tolerability endpoints investigated in the E-R analysis were confirmed hypoglycemic adverse events (AEs) (plasma glucose \3.9 mM and/or assistance required), events consistent with urinary tract infection (UTI; using a prospectively defined search of 73 preferred terms), events consistent with genital infection (using a prospectively defined search of 89 preferred terms), and events consistent with volume depletion (all on-treatment AEs, using eight preferred terms).
The safety/tolerability endpoints considered in the E-R analysis were included as dichotomous endpoints (i.e., participant-reported AEs: any AE during study, single yes/no datapoint), and were analyzed using a logistic regression model [19, 22] . Odds ratios (ORs) for an event on empagliflozin treatment were calculated and independent variables were incorporated into the model via the logit function. The covariates evaluated included age, Asian race, renal function stage, sex, concomitant oral (metformin and SU) and parenteral (insulin) antidiabetic agents, and empagliflozin exposure. Covariate effects were included using the full covariate modeling approach [19, 22] . If covariates were included, they were entered additively using the formula below. It should be noted that non-exposure related covariates were only included for the purpose of adjusting the event rates to allow for proper assessment of the effect of exposure on the different AE rates. These non-exposure related covariates could, therefore, be regarded solely as adjustment factors and not as points for inference. Selection of adjustment covariates was, therefore, data driven and dependent on the endpoint that was analyzed.
Note also that this article is based on the analysis of data from previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
The population PK analysis was based on 12,503 empagliflozin plasma concentrations from two Phase I, four Phase II, and four Phase III studies (2761 patients on active empagliflozin) (Table 1) [7, 8, 11-13, 15, 17, 24] . Doses of orally administered empagliflozin ranged from 1 to 100 mg, with 1129 patients (40.9%) receiving 10 mg and 1269 patients (46.0%) receiving 25 mg empagliflozin once daily.
Patients receiving placebo were not included in the PK analysis.
Population PK Analysis
The PK of empagliflozin was well described by a two-compartment model with first-order Figure 1 shows the estimated covariate effects on CL/F (Fig. 1a) and relative empagliflozin exposure (Fig. 1b) The analysis also showed statistically significant relationships between BMI, total protein, age, female sex, current smoking status, Asian race, and AP and CL/F (95% CIs for these estimates did not include the null value). However, the magnitudes of these covariate effects were minor, with differences within these covariate groups between 0.8 and 1.25 of the normalized CL/F or AUC ss at the extreme covariate levels (Fig. 1) . The other covariate effects (ALT, AST, LDH, and previous smoking history) were non-significant. Estimated covariate effects on parameters not affecting AUC ss (V 2 /F, V 3 / F, and k a ) are included in Table S1 in the supplementary material. (Fig. S3 in the supplementary material) . The performance of the final PK/PD models comprising all data was evaluated using goodness of fit plots and visual predictive checks, which indicated that the model adequately described the efficacy data (Figs. S4-S7 in the supplementary material).
The continuous and categorical covariates for the PK/PD datasets are summarized in Table 2 and Table S2 in the supplementary material. For the population PK/PD efficacy (Table S3 in the supplementary material, and Fig. 2 ).
The maximum reduction (G max ) in FPG with empagliflozin therapy was estimated to be 22%.
G max was mainly affected by BFPG and eGFR;
G max was estimated to increase with increasing BFPG and decrease with decreasing eGFR.
Significant but small effects on G max were observed with metformin ? SU co-treatment, sex, BMI, and age. Other covariates (metformin or pioglitazone co-treatment, duration of T2DM, and Asian race) had no significant effect on G max of FPG.
Glycated BFPG, 8 mM; Fig. 3 ).
To investigate the influence of eGFR and age on HbA1c lowering, deterministic simulations were performed to illustrate the E-R after 24 weeks of treatment ( (Table 3) .
Exposure-Response Analysis (Safety)
In total, 4065 patients were evaluable in the safety/tolerability dataset (2584 on active empagliflozin therapy and 1481 on placebo).
Overall safety/tolerability event rates were: 11.5% (n = 466) for confirmed hypoglycemic AEs, 8.09% (n = 329) for events consistent with UTI, 2.85% (n = 116) for events consistent with genital infection, and 0.839% (n = 34 events reported from a dataset of 4054 patients) for events consistent with volume depletion. The impact of empagliflozin exposure on the tolerability endpoints was adequately described by logistic regression models (Fig. S9  in the supplementary material) 
DISCUSSION
The population PK and E-R for the efficacy and safety/tolerability of empagliflozin was investigated in patients with T2DM. The aims of the population PK analysis were to describe the PK of empagliflozin in patients with T2DM
and to quantify the effects of covariates. The PK of empagliflozin was well described by a two-compartment model with first-order absorption. The covariate analysis indicated that no dose adjustment is necessary for the evaluated covariates. Variability in the CL/F, and hence, AUC ss of empagliflozin was statistically significantly affected by eGFR, BMI, total protein, age, female sex, current smoking, and Asian race, but their clinical impact on empagliflozin exposure was minor (i.e., 80-125%). The only statistically significant ) at screening were assigned to 10-mg empagliflozin, and subsequently, had eGFR values between 49 and 58 mL/ min/1.73 m 2 at the baseline visit just prior to treatment initiation. These patients were therefore categorized as having moderate renal impairment, but continued on the randomized 10-mg dose. As simulations are summarized as the change from baseline (defined as start of treatment) HbA1c values, stratification of the patients with respect to the baseline renal impairment category was completed, and hence, five patients categorized as having moderate renal impairment were treated with 10-mg empagliflozin 
CONCLUSIONS
In conclusion, the population PK and E-R models adequately described the PK, efficacy (reductions in FPG and HbA1c), and tolerability (hypoglycemia, genital infections, UTI, volume depletion) of empagliflozin. Variability in empagliflozin exposure was primarily affected by eGFR (increase in exposure less than twofold in patients with severe renal impairment).
Compared with placebo, empagliflozin therapy was associated with an exposure-independent increase in the incidence of genital infection and no significant change in the risk of UTI, hypoglycemia, or volume depletion. Consistent with the mode of action, the efficacy of empagliflozin was increased with elevated glucose levels and attenuated with decreasing renal function despite an increase in its exposure (less than twofold), but was still maintained to nearly half the maximal effect with eGFR as low as 30 mL/min/1.73 m 2 . All other investigated covariates including sex, BMI, race, and age did not alter the PK or efficacy of empagliflozin to a clinically relevant extent. Overall, no dose adjustment is required for empagliflozin in the patient population for which the drug is approved.
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